OLMA
NASDAQ · Biotechnology
Olema Pharmaceuticals Inc
$14.90
-0.23 (-1.52%)
Open$14.99
Previous Close$15.13
Day High$15.47
Day Low$14.85
52W High$36.26
52W Low$3.89
Volume—
Avg Volume814.5K
Market Cap1.32B
P/E Ratio—
EPS$-1.86
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+12.8% upside
Current
$14.90
$14.90
Target
$16.81
$16.81
$15.48
$16.81 avg
$21.94
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 273.28M | 252.57M | 215.43M |
| Net Income | -27,842,007 | -24,319,116 | -27,608,347 |
| Profit Margin | -10.2% | -9.6% | -12.8% |
| EBITDA | -48,708,771 | -44,721,101 | -36,525,999 |
| Free Cash Flow | -19,743,741 | -20,820,819 | -13,833,937 |
| Rev Growth | +22.4% | +21.1% | -4.4% |
| Debt/Equity | 0.25 | 0.24 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |